

CURRICULUM VITAE
ROBERT EMORY TAYLOR, M.D., Ph.D., F.A.C.P., F.C.P.

Chairman, Department of Pharmacology
Professor of Pharmacology and Medicine
Director, Howard University Collaborative Alcohol Research Center
Howard University College of Medicine
520 W Street, N.W., Suite 3408
Washington, D.C. 20059
(202)-806-6311
(202)-806-4453.fax
rtaylor@howard.edu
<http://hucmlrc.howard.edu/hucm/pharm/>

BIRTHPLACE:

.....

EDUCATION:

M.D. 1976 - Vanderbilt University School of Medicine, Nashville, TN., **Medicine**
Ph.D. 1972 - Purdue University, Lafayette, IN., **Pharmacology/Toxicology**
M.S. 1968 - Butler University, Indianapolis, IN., **Pharmacology**
B.S. 1965 - Butler University, Indianapolis, IN., **Pharmacy**

POSTDOCTORAL TRAINING:

Fellow, Clinical Coagulation-Hematology, Center for Hemostasis-Thrombosis
North Carolina Memorial Hospital, University of North Carolina at Chapel Hill, School of Medicine, July
1979 - June 1980.

Intern and Resident, Internal Medicine
Vanderbilt University Hospital and Affiliated Hospitals, July 1976 - June, 1979.

Smith, Kline & French Post Doctoral Fellow, Department of Pharmacology,
Vanderbilt University, December, 1971 - November, 1972.

CERTIFICATION:

Licensed Physician - Tennessee (1977), North Carolina (1979), District of Columbia (1980), Maryland
(1985).

Registered Pharmacist - Indiana (1965).

Diplomate, National Board of Medical Examiners (1977).

American Board of Internal Medicine, Internal Medicine, (1981).

PROFESSIONAL AND RESEARCH EXPERIENCE:

July, 1992 - Present Chairman, Department of Pharmacology
Director, Graduate Studies, Department of Pharmacology
Howard University College of Medicine

January 1992 - June 1992
Interim Chairman, Department of Pharmacology
Howard University College of Medicine

June 1980 – August 2002 Director, Division of Clinical Pharmacology and Toxicology
Department of Medicine and Pharmacology, Howard University Hospital

CURRICULUM VITAE
R.E. Taylor, M.D., Ph.D

- July 1999- Present Professor of Pharmacology and Medicine, Howard University College of Medicine.
- July 1986 – June 1999 Associate Professor of Pharmacology and Medicine, Howard University College of Medicine.
- July 1992 - Present Graduate Professor of Pharmacology, Graduate School of Arts and Sciences; Associate Professor, 1987-1992; Assistant Professor, 1982 - 1987.
- July 1998 - Present Medical Director, Oral Anticoagulant Service, Howard University Hospital, Department of Pharmacy Services
- October 1997- Present Program Director and Principal Investigator, Howard University-NIAAA Collaborative Minority Alcohol Research Development Center (CMIARD).
- January 1997- Present Program Director and Principal Investigator, Howard University-SmithKline Beecham Fellowship In Clinical Pharmacology and Pharmaceutical Medicine
- July, 1992 - June 1995 Program Director and Principal Investigator, Glaxo Inc-Howard University Physician Fellowship Program in Clinical Pharmacology and Pharmaceutical Medicine
- July 1988 - June 1992 Director, Therapeutic Apheresis Unit, Howard University Hospital, Co-Director, 1982 -1988.
- June 1980 - June 1986 Assistant Professor of Pharmacology (Primary Appointment) and Medicine (WOC), Howard University College of Medicine.
- July 1979 - June 1980 Fellow, Clinical Coagulation-Hematology, North Carolina Memorial Hospital, University of North Carolina, School of Medicine, Chapel Hill, N.C. Clinical Fellowship in Disorders of Hemostasis and Thrombosis.

- June 1972 - June 1979 Associate in Medicine, Department of Medicine, Division of Hematology, Vanderbilt University Medical School, Nashville Tennessee. Pharmacology of Human Blood Platelets and the Role of Cyclic Nucleotides. Mechanisms of Thrombosis and Hemostasis.
- June 1975 - June 1976 Associate in Clinical Pharmacology, Departments of Medicine and Pharmacology, Division of Clinical Pharmacology, Vanderbilt University Medical School, Nashville, TN. Role of Prostaglandins in Human Platelet Function.
- December 1972 - July 1974 Associate in Pharmacology, Departments of Pharmacology and Tennessee Neuropsychiatric Institute, Vanderbilt University Medical School, Nashville, TN. Role of Cyclic Nucleotide Systems in the Mechanisms of Action of Psychotropic Drugs and Hallucinogens.

- December 1971- November 1972

CURRICULUM VITAE
R.E. Taylor, M.D., Ph.D

Fellow, Smith, Kline & French Foundation, Vanderbilt University School of Medicine, Department of Pharmacology, Nashville, TN. Relation of Adenylate Cyclase and Cyclic AMP to Hormone Action.

September 1968 -December 1971

Predoctoral Fellow, Environmental Health and Toxicology, Public Health Service, Purdue University, Department of Pharmacology and Toxicology, Lafayette, IN. Effects of Hormones and Drugs on Carbohydrate Metabolism.

June 1965 - August 1968

Assistant Manager and Pharmacist, Hook Drug Co., Indianapolis, IN.

HOSPITAL AND CENTER AFFILIATION:

Attending Physician - Howard University Hospital, 1980 – present

Attending Physician – NIH Clinical Center, Laboratory of Clinical Sciences, NIAAA, 4/2004- present

Attending Physician - District of Columbia General Hospital, 1980 - 1986

Member, Howard University Cancer Center, 1993 – present

Director, Howard University Collaborative Alcohol Research Center, 1997- present

OTHER PROFESSIONAL EXPERIENCES (Selected)

Chairman, Symposium "Molecular Genetics in Clinical Medicine," National Medical Association, Basic Science Section, New Orleans, Louisiana, August, 2, 1998.

Vice-Chairman, Symposium "The Application of Basic Science to Problems in Clinical Medicine," National Medical Association, Basic Science Section, Atlanta, Georgia, July 30, 1995.

Moderator, Conference "Forum on the Status of Coronary Heart Disease in Blacks: A Blueprint for Forging Linkages to Improve Medical Management and To Enhance Public Health Action, " National Heart, Lung, and Blood Institute, Health Education Branch, Washington, D.C., March 31, 1995. (Proceedings published Journal of the National Medical Association, August, 1995, vol. 87, No. 8 (supplement).

Panelist, National Institutes of Health Technology Assessment Workshop on the **Persian Gulf Experience and Health**, NIH, Bethesda, Maryland, April 26-29, 1994.

Co-Chairman, Conference on the Inclusion of Women and Minorities in Clinical Trials Research, Georgetown University; Sponsors: Georgetown University, Howard University, Office for Protection from Research Risks, National Institutes of Health, Food and Drug Administration, June 28-29, 1993.

Chairman, Symposium "Clinical Trials to Medical Practice: How To Make the Transition," National Medical Association, Basic Science Section, Orlando, Florida, July 24, 1994.

Chairman, Symposium "Molecular Biology and Biotechnology in the Practice of Medicine," National Medical Association, Basic Science Section, San Francisco, California, August, 1992.

Chairman, Symposium "Molecular Biology, Biotechnology and the Practice of Medicine," National Medical Association, Basic Science Section, Indianapolis, Indiana, July, 1991.

CURRICULUM VITAE
R.E. Taylor, M.D., Ph.D

Chairman, Symposium "Innovative Medical Therapeutics for the 1990's," National Medical Association, Basic Science Section, Las Vegas, Nevada, July, 1990.

Chairman, Symposium "Practical Approaches to Antibiotic Utilization," National Medical Association, Basic Science Section, Orlando Florida, July, 1989.

Chairman, Symposium "Update in Clinical Pharmacology," National Medical Association Convention, Basic Science Section, Los Angeles, July, 1988.

Chief Proctor, American Board of Internal Medicine, Certification and Subspecialty Examinations, Howard University College of Medicine Test Site, 1986-1988.

Member, Scientific Advisory Committee, THE CHEMTOX DATABASE™, 1983 - 1986.

Chairman, Institutional Review Board for Human Research, Washington Center for Clinical Studies, Pharmakinetix, Inc., 1983 - 1985.

Chairman, Conference: "Educating Patients 1984 - The Practitioner's Perspective," Howard University College of Medicine, Food and Drug Administration, National Medical Association, June 9, 1984.

Chairman, Conference: "Focus on Health Care Issues: Sodium and Hypertension," Food and Drug Administration, National Medical Association, Howard University College of Medicine, February 26, 1982.

Adjunct Associate Professor of Clinical Pharmacology, School of Pharmacy, Florida A & M University, Tallahassee, Florida, 1974-1982.

Participant, Gordon Research Conference on Cyclic AMP, Tilton, N.H. 1974.

SCIENTIFIC REVIEW COMMITTEES (Selected)

Chairman, US Food and Drug Administration Advisory Committee for Pharmaceutical Science; November 1995-October 1999; **Chairman**, January 1997- October 1999.

Chairman, Toxicology Study Section, National Institutes of Health, July 1989 - June, 1991; Member, July 1987 - June, 1991.

Chairman, Safety and Occupational Health Study Section, National Institute for Occupational Safety and Health (NIOSH), Public Health Service, Center for Disease Control, July 1983 - June 1984; Member, 1980 - June 1984.

Chairman, Ad Hoc Technical Review Group, "Isotretinoin--Basal Cell Carcinoma Prevention Study," National Cancer Institute, National Institutes of Health, June 23-24, 1983.

Chairman, Ad Hoc Technical Review Group, "Human Studies of Diet and Nutrition: Selenium Pharmacokinetics and Chronic Selenium Supplementation Studies," National Cancer Institute, National Institutes of Health, April 29, 1983.

Chairman, Special Study Section, National Cancer Institute, "Safety and Protocol Review Committee for Chemoprevention Projects," October 14, 1983.

**

Member, National Advisory Council on Alcohol Abuse and Alcoholism, National Institute on Alcohol Abuse and Alcoholism (NIAAA), NIH, 11/2002-2006.

CURRICULUM VITAE
R.E. Taylor, M.D., Ph.D

Member, U.S. Army Medical Research and Materiel Command Breast Cancer Research Program, Clinical and Experimental Therapeutics # 5 Review Panel, September 5-8, 1997.

Member, National Board of Medical Examiners (NBME) and USMLE Step I Pharmacology Test Committee, 1996-1999.

Member, National Academy of Sciences, Institute of Medicine, Committee on Pharmacokinetics and Drug Interactions in the Elderly, December 19, 1996- December 31, 1997.

Member, Center For Substance Abuse Treatment (CSAT), TIPs Consensus Panel on "Alcohol and Other Drug Screening, Intervention, Referral, and Followup in the Primary Care Setting", May 1996 - Present.

Member, National Academy of Sciences, Institute of Medicine, Committee on Toxicology and Environmental Health Information Resources for Health Professionals, November, 1995 - April, 1997.

Member, Workers' Family Protection Task Force, National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention, September 15, 1994 - June 30, 1998.

Member/Delegate U.S. Pharmacopeia Conference, 1995-2000; Participant Quinquennial Meeting, March 8-12, 1995, Washington, DC.

Member, National Academy of Science/Institute of Medicine Planning Committee to advise the National Library of Medicine on Toxicology and Environmental Health Information Programs, Washington, DC, November 21, 1994.

Member, Board of Scientific Counselors of the Office of the Assistant Secretary for Health, National Toxicology Program, National Institute of Environmental Health Sciences, DHHS, July 1, 1992 -December 12, 1996.

Member, Toxicology Information Outreach Advisory Panel, National Library of Medicine, January, 1992 - Present.

Member, Health Reviewers Reserve, National Institutes of Health, July 1, 1991- June 30, 1995.

Member, Advisory Board, Biomedical Research Center (RCMI), Xavier University of Louisiana, June, 1989 - 1991.

Member, Committee on Toxicology, Board on Environmental Studies and Toxicology, National Academy of Sciences, National Research Council, August 1, 1986- July 31, 1989.

Member, National Institutes of Health Peer Review System Study Committee, Office of the Director, National Institutes of Health, February 1989 - 1990.

Member, Special Study Section, National Institute for Occupational Safety and Health (NIOSH), February, 1985.

Member, Special Study Section, National Institute on Aging, October 1983.

Member, Special Study Section, National Cancer Institute, April and June, 1983.

Member, Special Study Section, National Institute of Neurological, Communicative Disorders & Stroke, November 1982.

CURRICULUM VITAE
R.E. Taylor, M.D., Ph.D

Reviewer, Contracts Technical Review Group, "Performance of Protocol Toxicology Studies," National Cancer Institute, April, 1987.

Reviewer, Small Business Innovative Research, Pharmacology Study Section, Division of Research Grants, National Institutes of Health, April, 1987, August, 1987, December, 1987, April, 1988, and March, 1989.

Reviewer, National Heart Lung and Blood Institute, Hematology Study Section, February, 1986.

EDITORIAL APPOINTMENTS

Member, Editorial Board, **Journal of the National Medical Association**, 1989 – 1994; 1999-2004.

Reviewer, **Clinical Pharmacology and Therapeutics**, 1989 - 1990.

Reviewer, **Clinical Research**, 1988-1989.

Member, Editorial Board, **Environmental Health Perspectives**, NIEHS, NIH, 1997- 2003.

Member, Editorial Advisory Board, **Alcohol Health & Research World**, NIAAA, NIH, 1998-2003.

Reviewer, **Journal of the American Medical Association** (JAMA), 2000-2001.

Reviewer, **Alcoholism: Clinical and Experimental Research**, 2001-Present.

Reviewer, **Progress in Neuro-Psychopharmacology & Biological Psychiatry**, 2004

CONSULTANT APPOINTMENTS

Science Advisor to the Director (Dr. Ting-Kai Li), National Institute on Alcohol Abuse and Alcoholism (NIAAA), NIH, 9/2003-Present.

Member, Advisory Board, Training Program in Clinical Pharmacology, The Johns Hopkins University, School of Medicine. 9/2003- Present

Member, Search Committee, Chief, Section on Behavioral Science and Genetics, Laboratory of Integrative Neuroscience, Division of Intramural Clinical and Biological Research, NIAAA, NIH, 5/2002-11/2002

Member, Search Committee, Track Position in Psychiatric Genetics, Laboratory of Integrative Neuroscience, Division of Intramural Clinical and Biological Research, NIAAA, NIH, 12/2002- Present.

Faculty Fellow, LCME, February 2001, Site Visit to University of Missouri@Columbia School of Medicine.

Consultant, Pharmaceutical Research Manufacturers Association (PhRMA), 6/2000-9/2000.

Consultant, Office of the Sr. Vice President and Dean, Meharry Medical College, Nashville, April 2000.

Expert Consultant, Barr Laboratories, Inc. September 1998- 2002.

Consultant, Glaxo Research Institute Inc., Research Triangle Park, North Carolina, Physician Pharmaceutical Collaborative Programs, 1994 - 1995.

Consultant, Office for the Protection of Research Risks, U.S. Department of Health and Human Services, September , 1988.

Scientific Consultant, Eli Lilly Company, Indianapolis, 1976 - 1977.

COMMITTEE APPOINTMENTS:

University Wide Committees

Chairman, Institutional Review Board for Human Research (IRB), Howard University, 1985 - present;

Member, 1981 - Present.

Co-Chair, Biomedical Sciences Subcommittee, Research Think Tank, April 2002- Present

Member, University Self-Study Task Force, Subcommittee on Teaching and Research, February 1988 - 1989.

Member, Search Committee for Dean, School of Pharmacy and Pharmacal Sciences, 1992-1994.

Member, Search Committee for Associate Vice President for Research, 1997- 1999

CURRICULUM VITAE
R.E. Taylor, M.D., Ph.D

Member, University-wide Advisory Committee for *Strategic Framework for Action-II*, September 2000-present

Member, Advisory Board, Research Program in the Epidemiology and Prevention of Drug Abuse (NIDA), March 2003-Present.

College of Medicine

Chairman, Search Committee for Chairman, Department of Pathology, 2003- Present

Unit Director, Unit One- General Principles of Genetics, Microbiology, Pathology and Pharmacology, Sophomore Medical Student Integrated Curriculum, 5 weeks-full time, September-October 2002- present.

Member, Executive Committee, College of Medicine, 1997- Present

Chairman, Ad Hoc Committee on Academic Tracks in the College of Medicine, 1995 - Present

Member, Integrated Advanced Information Management Systems Project (IAIMS), 1995 – Present

Chairman, Search Committee for Chairman, Department of Pathology, 2002-Present.

Chairman, Exhibits Committee and **Chairman**, Historical Committee, 125th Howard University College of Medicine Commemorative Exhibition, 1994 – 1996

Member, College of Medicine, Liaison Committee on Medical Education (LCME), Task Force and Steering Committee; **Chairman**, Subcommittee on Resources: Faculty, 1993-1995.

Chairman, College of Medicine LCME Self Study, Sub-Committee on Resources: Faculty, 1987; Subcommittee on Basic Science Departments, 2000-2002.

Member, Search Committee for Chairman, Department of Medicine, 2003- Present.

Member, Search Committee for Chairman, Department of Medicine, 1986 - 1987.

Member, Search Committee for Director and Chairman, Howard University Cancer Center, 1984 - 1985.

Member, Search Committee for Associate Clinical Director, Howard University Cancer Center, 1986 - 1987.

Member, Curriculum Committee, College of Medicine, 1983 - 1984; 1986-1988.

Member, Admissions Committee, College of Medicine, 1982 - 1983; 1989 - 1990

Member, Committee on Research Space, 1983 - 1991

Member, Scientific Advisory Committee, Clinical Research Center, 1984 - 1986.

Member, Dean's Committee on Computer Applications to Medical Education and Research, 1989-1991

Member, Oversight Committee, Howard University/Johns Hopkins Comprehensive Cancer Center Partnership, 2000-present

Graduate School of Arts and Sciences:

Member, Joint Graduate School/Medical School M.D./Ph.D. Planning Committee, 1993 - Present.

CURRICULUM VITAE
R.E. Taylor, M.D., Ph.D

Member, Advisory Committee, Collaborative Core Unit, Faculty Training in State-of-the-Art Techniques of Molecular Biotechnology, 1992 - Present.

Hospital Committees:

Chairman, Pharmacy and Therapeutics Committee, Howard University Hospital, 1980- 1992; Member 1992 - Present.

Chairman, Drug Utilization Subcommittee, 1986 -1990; **Chairman**, Antibiotic Subcommittee, 1986-present; **Chairman**, Adverse Drug Reaction Subcommittee 1992-1993.

Member, Executive Committee, Howard University Hospital, 1980 - 1991.

Member, Infection Control Committee, 1984 - 1986.

Member, Bioethics Committee, 1985 - 1991.

Departmental Committees:

Department of Pharmacology

Member, Executive Committee, 1985 - 1987; 1988 - 1992.

Member, Promotions Committee, 1987 - 1992.

Course Coordinator, General and Systemic Pharmacology for Sophomore Medical Students, 1985 - 2001.

Course Coordinator, Introduction to Pharmacology for Sophomore Medical Students, 1985 - 2001.

Course Coordinator, Fundamentals of Toxicology, Howard University, College of Medicine, Department of Pharmacology and Howard University School of Continuing Education, March-April, 1993.

Department of Medicine

Member, Research Committee, 1987 - 1992

Member, Education Committee, 1986 - 1990.

Chairman, Promotions Committee, 1987 - 89; Member, 1986 - 1993

Member, Executive Committee, 1984 - 1992.

OTHER COMMITTEES:

Member, Information Systems and Technology Working Group, **Academic Medicine and Managed Care Forum**, AetnaUSHealthcare, 1997 - 1999.

Co-Director, Third International Interdisciplinary Conference on Hypertension in Blacks, The International Society on Hypertension in Blacks, April 1988.

Delegate, The United States Pharmacopeial Commission Convention, November 1985.

Member, Advisory Committee on Grassroots/Medical School Representatives, American Federation for Clinical Research (AFCR), 1983 - 1992.

CURRICULUM VITAE
R.E. Taylor, M.D., Ph.D

Member, Board of Directors, National Council on Patient Information and Education, 1984 -87; Member, Annual Conference Planning Committee, National Council on Patient Information and Education, 1985.

PROFESSIONAL DEVELOPMENT:

“Executive Development Seminar for Associate Deans and Department Chairs”, Jointly Sponsored by AAMC and Harvard Medical School, Department of Continuing Education, October 10-15, 2003.

“Academic and Administrative Leadership in the Academy: Chairing the Academic Department”, Office of the Provost, Howard University, November 21, 2002.

“The Evolving Role of the Basic Science Department Chair”, Basic Science Chairs Leadership Forum, AAMC Council of Academic Societies, October 11-13, 2002, Philadelphia.

“Leading a Quality Department”, Association for Medical School Pharmacology, February 6-8, 2000, Sea island, GA.

“Biological Vulnerability to Alcoholism and Drug Addiction”, FASEB Summer Conference, August 1-6, 1999, Copper Mountain, Colorado.

Workshop on the Teaching of Pharmacology to Medical Students, Association for Medical School Pharmacology, Sea Island, GA, February 2-3, 1998.

In Vivo Pharmacokinetics of Alcohol: Determinants and Analysis of Blood Alcohol Concentrations after Social Drinking, NIAAA, Bethesda, MD, December 2-3, 1997.

Medical Informatics Short Course, Department of Medical Informatics, Stanford University School of Medicine, Palo Alto, CA, August 18- 22, 1997.

Legal Issues in Faculty Tenure and Compensation, Deans Roundtable, AAMC, Leesburg, VA, January 24, 1997.

Tenure, Compensation and Career Pathways: Reexamining the Faculty Employment Relationship in Academic Medicine, AAMC, McLean, VA , February 4-6, 1996.

NIAAA/HRSA “Physicians Guide to Helping Patients with Alcohol Problems” Training Workshop, Miami, February 27-28, 1996.

Chairing the Academic Department, American Council on Education, Washington, June 18-21, 1996.

Reassessing the Biomedical Ph.D. Degree: Doing the Right Thing, American Association of Medical Colleges, Ft Lauderdale, October 7-9, 1995.

International Research Concerns: Ethical Issues in the Protection of Human Subjects, Johns Hopkins School of Hygiene and Public Health, Baltimore, Maryland, November 13-14, 1995.

Ph.D Education in American Medical Colleges, American Association of Medical Colleges, Ft. Lauderdale, Florida, October 8-10, 1994.

Pharmacokinetics Analysis: Accelerating Drug Development in Clinical Trials, Cambridge Healthtech Institute, Washington, D.C., October 6-7, 1994.

Franklin Quest Institute, Time Management, Baltimore, Maryland, September 22, 1993.

CURRICULUM VITAE
R.E. Taylor, M.D., Ph.D

Current Issues in Laboratory Medicine 1993: Diagnosis and Management of Bleeding and Thromboembolic Disorders, Washington Hospital Center, April 24, 1993.

Institutional Review Board (IRB) Review: The Changes and the Challenges, PRIM&R, Boston Massachusetts, December 10-11, 1992.

Recombinant DNA and Polymerase Chain Reaction (PCR) Methods for Diagnosis of Microbial and Neoplastic Disease (Clinical Biotechnology II), The Catholic University of America, June 8-12, 1992.

Integrating the Basic Sciences and Clinical Medicine: Breaking Down the Barriers, Northeast Group on Educational Affairs, Johns Hopkins Medical Education, AAMC, Baltimore, Maryland, March 30-April 1, 1992.

Kidney Disease and Hypertension in Blacks, NIH, National Institutes of Diabetes and Digestive and Kidney Diseases, Division of Kidney, Urologic and Hematologic Diseases, Washington, D.C., December 11-13, 1991.

Molecular Biology for Risk Assessors, Society for Risk Management, Baltimore, Maryland, December 8, 1991.

Molecular Biology/Recombinant DNA Techniques I Workshop, Life Technologies Inc., GIBCO BRL, Germantown, Maryland, July 8-12, 1991.

Annual Review of Clinical Pharmacology Course, American College of Clinical Pharmacology, Rockville, Maryland, April 3, 1991.

Ophthalmology Workshop for the Emergency Physician, Georgetown University School of Medicine and Hospital, Washington, D.C., September 17, 1988.

Computer-Based Testing in Medical Education and Evaluation, National Board of Medical Examiners, Philadelphia, Pennsylvania, March 24, 1988.

"IRB's: New Challenges and Problems," PRIM&R and The Tufts University School of Medicine, Boston, Massachusetts, November 12-13, 1987.

Pharmacoepidemiology Course, Graduate Summer Program in Epidemiology, The Johns Hopkins University School of Hygiene and Public Health, Baltimore, Maryland, June 22 - July 11, 1987.

Concepts in Inhalation Toxicology Workshop, Lovelace Inhalation Toxicology Research Institute, Albuquerque, New Mexico, October 20-23, 1986.

"Management of Medical Emergencies-The First 12 Hours," American College of Physicians, Hilton Head, South Carolina, August 3-7, 1986.

"Dilemmas in Drug Development for Institutional Review Boards," PRIM&R and UMDNJ-Rutgers Medical School, April 10-11, 1986.

Physician Management Seminar, American Academy of Medical Directors, Providence, R.I., December 5 - 6, 1985.

Pharmacokinetics and Biopharmaceutics Workshop, American Society for Clinical Pharmacology and Therapeutics, University of Florida, St. Augustine, Florida, March 20 - 28, 1983.

Advanced High Pressure Liquid Chromatography Seminar, Waters Associates, 1983.

CURRICULUM VITAE
R.E. Taylor, M.D., Ph.D

Pfizer Patient Education Conference, Washington, D.C., November 4-5, 1982.

Haemonetics Research Institute, Advanced Component Pheresis Seminar, Boston, Mass., 1982.

American College of Physicians, Internal Medicine Review Course, Maui, Hawaii, August, 1982.

Institutional Review Boards and Human Subjects Research Workshop, Yale University School of Medicine and Hastings Institute, Colorado Springs, Colo., July 11 - 17, 1982.

Hemostasis Workshop, American Red Cross, Washington, D.C., May 10 - 12, 1981.

COMMUNITY PARTICIPATION:

Chairman ,Scientific Advisory Committee, Charles and Ella Latham Trust, Washington, D.C., 1992 - present

Member, Advisory Council to the Board of Directors, The CHARLEE Program of Washington, D.C., 1983 - 1986.

Member, Board of Directors, MacArthur Park Condominium Association, Washington, D.C., 1984 - 1985.

AWARDS, HONORS, SPECIAL RECOGNITION:

Recipient, **Distinguished Alumnus Award**, School of Pharmacy and Pharmacal Sciences, Purdue University, 1997.

Recipient , Health Plus HMO , "**1995 Outstanding Primary Care Physician**," for consistently high performance and quality of care, May 1995-96.

Honoree, "**Old Masters**" Program, Purdue University, 1991, in recognition of outstanding personal achievement and professional contributions as a model and inspiration for the next generation of leaders, November 3-6, 1991.

Recipient, **Kaiser-Permanente Award for Excellence in Teaching**, Howard University College of Medicine, November 12, 1987.

Recipient, **Commissioner's Special Citation**, Office of Health Affairs, Food and Drug Administration, "In recognition of extraordinary contributions to professional understanding of the importance of patient and drug information and the techniques for providing such information," June 1985.

USPHS Pre-Doctoral Fellowship, 1968 - 1971.

NIH Post-Doctoral Fellowship, 1972.

Smith, Kline & French Post Doctoral Fellowship, 1972.

Listed, **Outstanding Young Men of America**, 1975.

PROFESSIONAL SOCIETIES AND HONORARIES:

Fellow, American College of Clinical Pharmacology

Fellow, American College of Physicians.

Fellow, The Royal Society of Medicine

CURRICULUM VITAE
R.E. Taylor, M.D., Ph.D

Member, Alpha Omega Alpha (AOA) Medical Honor Society;

Member, Alpha Phi Omega, National Service Fraternity

Member, American Association for the Advancement of Science

Member, American Medical Informatics Association

Member, American Federation of Clinical Research

Member, American Society of Addiction Medicine

Member, American Society for Clinical Pharmacology and Therapeutics

Member, American Society of Hematology

Member, Association for Academic Minority Physicians

Member, Association of Black Cardiologists

Member, Association for Medical School Pharmacology

Representative, Council of Academic Societies, AAMC; **Representative**, National Caucus of Basic Biomedical Science Chairs; **Representative**, Ad Hoc Committee on Biomedical Research Funding, 1992-1997.

“Knowledge Objectives In Medical Pharmacology”, Committee on Essential Knowledge Base in Pharmacology, Member, Subcommittee on Clinical Pharmacology and Subcommittee on Drugs Acting on Blood and Blood Forming Organs, 1996- present.

Member, Executive Committee, Councilor, 2002-2004
Chair, Task Force on Membership, 2002- Present

Member, District of Columbia Medical Chirurgical Society.

Member, Medical Society of the District of Columbia; Member, Pharmacy and Therapeutics Committee, 1983 - 1985; Member, Educational Programs, 1988-89.

Member, International Society on Hypertension In Blacks, Inc

Member, International Society for Biomedical Research on Alcoholism (ISBRA)

Member, Kappa Alpha Psi Fraternity

Member, National Medical Association; **Chairman**, Basic Science Section, 1986 - 1994; Vice Chairman, 1995 to 1998; Chairman 1999-present.

Member, New York Academy of Sciences.

Member, Phi Delta Chi, Pharmacy Professional Fraternity.

Member, Research Society on Alcoholism (RSA); Co-Chair, Government Affairs and Advocacy Committee 2000-Present.

Member, Rho Chi, Pharmacy Honor Society.

Member, Sigma Xi, National Research Honor Society.

INVITED PRESENTATIONS GIVEN: (SELECTED)

“Pharmacological and Cultural Considerations in Alcohol Treatment Clinical Trials: Issues in Clinical Research related to Race and Ethnicity”. Alcoholism Treatment Research Priorities and Health Disparities. NIAAA. September 23-24, 2002. Washington, DC.

“Malt Liquor Pharmacokinetics in African Americans.” Emerging Research Topics on Malt Liquor and Other High Alcohol Content Beverages. NIAAA. March 10-12, 2002, Washington, DC.

“Biochemical Etiology of Alcoholism and Substance Abuse”. Combined Basic Science-Psychiatry Section-“Alcohol and Substance Abuse: from Theory to the Streets”, National Medical Association 105th Annual Meeting, Washington, D.C., August 13, 2000.

Discussant, “ Update on Psychopharmacology”, Psychiatry Section, National Medical Association Annual Meeting and Scientific Assembly, August 9, 1999.

Discussant, Workshop on “Biologic and Molecular Mechanisms for Sex Differences in Pharmacokinetics, Pharmacodynamics and Pharmacogenetics”, NIH, May 2-3, 1999.

“NSAIDS/COX-2 Antagonists”, 13th Annual W. Lester Henry, Jr., M.D. Symposium, “Current Management of Gut and Liver Disease”, Howard University Hospital, Washington, D.C., March 16, 1999.

“Molecular Genetics: Where are we in 1998?” Basic Science Section Symposium, “*Molecular Genetics in Clinical Medicine*”, 103rd Annual Meeting National Medical Association, New Orleans, Louisiana, August 2, 1998.

“The Research Enterprise”, Plenary Speaker, Howard University College of Medicine Retreat, Bethesda, May 31, 1998

“IRB Issues-Biomedical Experimentation in Human Subjects”, Panel on Consumer Protection in Genetic Testing, **The National Dialogue on Genetics**. Genetic Link: Establishing a Dialogue Between Ethnically Diverse Communities and Genetic Policy Makers, College Park, MD, March 21, 1998.

“Deans and Faculty Involvement are Key to Fund Raising Success”, Annual Retreat, Howard University Development Officers Advisory Council, Washington, September 23, 1997

“Under-utilization of Anticoagulants in the African-American Community- What Are We Doing Wrong? Internal Medicine, General Internal Medicine Symposium, 102nd Annual Meeting, National Medical Association, Honolulu, August 3, 1997.

“Anticoagulation and Acute Myocardial Infarction- Super Aspirin and Low Molecular Weight Heparins-Recent Advances“. Internal Medicine, Critical Care: New Developments in Acute Ischemic Syndromes, 102nd Annual Meeting, National Medical Association, Honolulu, August 3, 1997.

“Pharmacoinformatics: Implications for Education and Research in the Pharmacological Sciences for the 21st Century”, First International Conference on Pharmaceutical and Pharmacological Sciences (South Africa), Midrand, South Africa, September 23, 1996.

“Venous Thromboembolism- Pathophysiology, Prevention and Update on Therapy” Internal Medicine, Critical Care Symposium, “Treatment of Acute Ischemic Syndromes”, 101st Annual Meeting National Medical Association, Chicago, July 28, 1996.

CURRICULUM VITAE
R.E. Taylor, M.D., Ph.D

"Research Issues in Infectious Diseases & Drug Development", Family Practice Symposium "Infectious Diseases in the United States and South Africa", 100th Annual Meeting National Medical Association, Atlanta , August 1, 1995

"Research Programs and Other Initiatives in the Department of Pharmacology at Howard University" Food and Drug Administration, Center for Drug Evaluation and Research, Division of Toxicological Research , May 5, 1995.

"The Practitioner's Daily Clinical Trial: When N=1," Basic Science Symposium, "Clinical Trials to Medical Practice: How To Make the Transition." 99th Annual Meeting National Medical Association, Orlando, Florida, July 24, 1994.

"M.D. Fellowships in the Pharmaceutical Industry," Conference on Pharmaceutical Medicine in a Changing World, Pharmaceutical Manufacturer's Association Medical Section's Medical Relations Committee, Washington, D.C., November 29-30, 1993.

"New Drugs: 1991-1992, Basic Science Symposium, "Molecular Biology and Biotechnology in the Practice of Medicine," 97th Annual Meeting, National Medical Association, San Francisco, California, August 2, 1992.

"New Drugs: 1990-1991, Basic Science Symposium, "Molecular Biology, Biotechnology and the Practice of Medicine," 96th Annual Meeting, National Medical Association, Indianapolis, Indiana, July 28, 1991.

"New Drugs: The Year in Review: Antibiotics, Gastrointestinal Drugs and Other Drug Classes," Basic Science Symposium, "Innovative Medical Therapeutics for the 1990's," 95th Annual Meeting, National Medical Association, Las Vegas, Nevada, July 29, 1990.

"Sustaining the Quality of Peer Review: Viewpoints of Study Section Reviewers, Chairpersons, and Investigators," Referral & Review Branch Peer Review Meeting, National Institutes of Health, Division of Research Grants, May 7, 1990.

"Drug-Induced Illnesses: Prescription and Non-Prescription," Management of the Geriatric Patient Seminar, Howard University College of Medicine, Office of Continuing Medical Education, November 29, 1989.

"Adverse Reactions Related to Antibiotic Use," Basic Science Symposium, "Practical Approaches to Antibiotic Utilization," 94th Annual Meeting, National Medical Association, Orlando Florida, July 16, 1989.

"Drug Interactions and Adverse Drug Reactions," Annual Intensive Review Course for Practicing Physicians, Howard University College of Medicine, June 6, 1989.

"Thrombolytic Therapy in the Management of Pulmonary Embolism and Thrombotic Disorders; The Role of Streptokinase vs tPA," Basic Science Symposium, "Update and Recent Advances in Clinical Pharmacology, 93rd Annual Meeting, National Medical Association, Los Angeles, California, July 31, 1988.

"Abuse of Prescription Drugs," Annual Intensive Review Course for Practicing Physicians, Howard University College of Medicine, June 10, 1988.

Panel Member, "Mock IRB," Regional Workshop on the Protection of Human Subjects, May 12 -13, 1988, University of Maryland, Graduate School, Baltimore, sponsored by the Food and Drug Administration and the National Institutes of Health.

"Prescription Drug Abuse," On the Line, Black Entertainment Network (BET), November 2, 1987.

CURRICULUM VITAE
R.E. Taylor, M.D., Ph.D

"Generic Drugs - Pro and Con," WJLA-TV, Channel 7 Evening News, March, 1986.

"Drug Tolerance and Compatibility in the Elderly," Centennial Anniversary Seminar, The Practicing Physician in an Aging Population, D.C. Medico-Chirurgical Society, April 27, 1985.

"Drugs in the Elderly," the Fifteenth Annual Intensive Review Course for Practicing Physicians, Howard University College of Medicine, June 2 - 6, 1985.

"An Update of Cardiovascular Therapy in the Aging Population," Group Health Association, Washington, D.C., April, 1985.

"Rational Use of Beta Adrenergic Blockers in Black Hypertensives and Post Myocardial Infarction" The Fourth Annual Symposium: Recent Advances in Hypertension and Coronary Disease in Black Populations, Washington, D.C., October 2 - 3, 1984.

Panel Member, "Ethical Issues in Drug Research Including the Compassionate Use of FDA Investigational Drugs" and "The Boundary Between Clinical Practice and Research," Middle Atlantic Regional Institutional Review Board Workshop, Howard University and National Institutes of Health, Office for Protection of Research Risk, October 22 - 23, 1984.

Panel Member, Symposium: Selected Aspects of Antihypertensive Therapy: Implications for Prevention of Target Organ Damage in Black Patients, Upjohn Pharmaceuticals and National Medical Association, Washington, D.C., March 12, 1984.

"Therapeutic Drug Monitoring," University of Tennessee, Center for the Health Sciences, Chattanooga, Tennessee, July 1984.

"The Pathogenesis and Management of Acute Disseminated Intravascular Coagulation," University of Tennessee, Center for the Health Sciences, Chattanooga, Tennessee, July 1984.

Speaker, Potomac Valley Chapter, Myasthenia Gravis Foundation, February 1985 and April, 1983.

"Basic Pharmacokinetics," Twelfth Annual Intensive Review Course for Practicing Physicians, Howard University College of Medicine, June 1982.

"Clinical Pharmacology of the Corticosteroids," Clinical Symposium of Florida A & M University, School of Pharmacy, Tallahassee, Florida, February 1981.

"A Pharmacokinetics Approach to Pain Management" in The Sickle Cell Spectrum: A Family of Related Syndromes. Washington, D.C., September 24 - 26, 1981.

"Drug Interactions: Drugs Acting Through Adrenergic Mechanisms," Scientific Assembly, National Medical Association, Dallas, Texas, August, 1980.

OTHER CLINICAL RESPONSIBILITIES:

Ward Attending, General Medical Service, Department of Medicine, Howard University Hospital (one month per year, 1980-2003, full-time)

Ward Attending, General Medical Service, District of Columbia General Hospital/Howard Service (one month per year) (1980-87)

Clinical Pharmacology Consult Service, Howard University Hospital (monthly),

CURRICULUM VITAE
R.E. Taylor, M.D., Ph.D

1980 - present.

Preceptor, Physical Diagnosis for Sophomore Medical Students (IPC III, IV), 1980 - 1990

GRADUATE SCHOOL/POST DOCTORAL RESPONSIBILITIES

Preceptor, Doctoral Students in Pharmacology (1984 - present)

..... 1984-1988

Dissertation: Effect of Hydrogen Peroxide and Superoxide Radical on Human Blood Platelets in the Presence of Dihomo-Gamma-Linolenic Acid.

..... 1988 - 1991

Dissertation: Characterization of the Cholinergic System in Human Blood Platelets.

.....

----. 1994-1998

Dissertation: Excitotoxic Neurodegeneration Induced by Domoic Acid in Isolated Chick Embryo Retina

Preceptor, ECFMG Foundation Visiting Professor of Clinical Pharmacology (A. Massele, M.D., Ph.D., Professor of Clinical Pharmacology, University of Dar Es Salaam, Tanzania) July 1987- June 1988.

Principal Investigator and Preceptor Glaxo Fellowship Program, Fellows: Lisa Johnson, M.D., (1992-1994); V.J. Hingorani, M.D., Ph.D. (1994-1995); Getu Assefa, M.D. (2000-2001)

RESEARCH INTERESTS:

Pharmacology and Toxicology of Alcohol

Clinical Pharmacology of Antiplatelet and Antithrombotic Agents.

Role of Oxygen Free Radicals in Human Platelet Function.

Prostaglandins, Cyclic Nucleotides and Platelet Function.

Mechanisms of Thrombosis and Hemostasis

Medical Ethics

Pharmacokinetics/Experimental Therapeutics

Medical Informatics

Grant Support

Active

1) National Institutes of Health

National Institute on Alcohol Abuse & Alcoholism

1 U24 AA11898-03

(Robert E. Taylor- Principal Investigator)

9/30/97 - 8/31/04

30% effort

\$3,082,618 (total cost)

\$151,000 (yr06 supplement)

Ethnic Factors in Alcohol Abuse Among African Americans

This is a grant to establish an alcohol research center at Howard University, and supports several pilot research projects.

2) National Institutes of Health

National Institute on Alcohol Abuse and Alcoholism

1 R01 AA12553-01

9/30/99- 8/31/04

CURRICULUM VITAE
R.E. Taylor, M.D., Ph.D

(Robert E. Taylor- Principal Investigator) 15% effort
-----..... (total cost)

-----.....:**Novel Phenotypes for the Genetic Analysis of Alcoholism**

This is an Interactive Research Project Grant to conduct collaborative neuro-genetics research with SUNY Downstate, Indiana University, Washington University, and supports a unique research protocol involving behavioral genetics, cognitive neuroscience, and molecular genetics,

3) NIH-N01-AA-01016 9/20/2000-10/31/2004
National Institute on Alcohol Abuse and Alcoholism 5% effort
National Institutes of Health \$188,215 (total cost)
(Robert E. Taylor- Principal Investigator)

Collaborative Research Projects on Alcohol Treatment

This is a subcontract from the University of Texas Health Sciences Center at San Antonio. The primary contract is from NIAAA awarded for training select Howard faculty and personnel in alcohol treatment research methodologies. This is a two-year project (\$188,215)

4) NIH-R21-AA-13531 9/31/2001-9/30/2004
National Institute on Alcohol Abuse and Alcoholism 20% effort
National Institutes of Health \$453,000 (total cost)
(Robert E. Taylor- Principal Investigator)

Malt Liquor Preference-Pharmacokinetics in African-Americans

This is an exploratory grant to study the pharmacokinetics of various malt liquor formulations in a cohort of healthy young African-American males and females, using a oral consumption model and a crossover design.

5). NIH-P20-AA014643 9/30/2003-8/31/2008
National Institute on Alcohol Abuse and Alcoholism 35% effort
National Institutes of Health \$6,501,968 (total cost)
(Robert E. Taylor- Principal Investigator)

Biological Determinants of Alcohol Action in Minorities

This is a competitive second 5 year award to continue the activities of the Howard University Collaborative Alcohol Research Center. The award supports six individual faculty research projects as part of a comprehensive Research Component, an administrative core, a science education component, and a faculty and career development component.

6). 1 R03 AA015114 4/1/2004- 3/31/2005
National Institute on Alcohol Abuse and Alcoholism 10% effort
National Institutes of Health \$37,250
(Robert E. Taylor- Principal Investigator)

Alcohol Intervention in an Inner City Emergency Room

This is a multi-center clinical trial to test the effectiveness of alcohol screening and brief intervention in a high- risk emergency room population.

Recent

1) DAMD17-94-J-4495 9/30/94-10/29/98
(Robert E. Taylor- Principal Investigator) 20% effort

CURRICULUM VITAE
R.E. Taylor, M.D., Ph.D

U.S. Army Medical Research
Acquisition Activity
\$772,186 (total cost)

New Therapeutic Approaches & Prognostic Assays for Breast Cancer: Radiolabeled Ligands and Antibodies and Quantitative PCR

The major goals of this project are to develop molecular biological probes of the estrogen receptors and other potential receptors which have prognostic and therapeutic potential.

- 2) Memorandum of Understanding 5/14/97-6/13/98
(Robert E. Taylor- Principal Investigator) 10% effort

Minority Investigator Collaborative Alcohol (MICAR) Program - Equipment

This is a contract to establish a molecular neuropharmacology alcohol research laboratory in the Department of Pharmacology.

- 3) National Institutes of Health 9/30/98 - 8/31/1999
National Institute on Alcohol Abuse & Alcoholism 30% effort
1 U24 AA1189 Grant amount: \$120,000
(Robert E. Taylor- Principal Investigator)

Collaborative Study on the Genetics of Alcoholism (COGA)

This grant supplements the above grant and provides research activities designed to link genetic factors as a cause of alcoholism.

- 4) Howard University, Office of the Provost 4/1/98 - 12/31/98
Fund for Academic Excellence 5% effort
(Robert E. Taylor- Principal Investigator)

Certificate Program in Alcohol Studies: Development of the Model

This is an award to develop a 12 credit hour certificate program into the science of alcohol and alcoholism

- 5) Subcontract 1- RO1- CA 82689-01S1 10/1/98- 7/31/00
National Institutes of Health 15%
National Cancer Institute Award Amount \$258,274
(Robert E. Taylor- Principal Investigator)

Immunohistochemical Coorelates of Prostate Cancer Progression: Studies in a Biracial Population

This is a subcontract from the Louisiana State University Health Sciences Center at New Orleans/Stanley S. Scott Cancer Center. The primary contract from NCI was awarded to study the presence of molecular markers in prostate cancer tissue in a retrospective African-American cohort at Howard University. This is a two-year project (-----)

Training Grants

- 1) Collaborative Agreement July, 1992 - June 1995
(Robert E. Taylor- Principal Investigator) **Glaxo Pharmaceutical Co.**
10% effort
Award Amount:

Howard University - Glaxo Physician Fellowship Program in Clinical Pharmacology and Pharmaceutical Pharmacology

CURRICULUM VITAE
R.E. Taylor, M.D., Ph.D

This is a training grant to fund M.D. fellowships in clinical pharmacology & pharmaceutical medicine.

- | | |
|--|---|
| 2) Collaborative Agreement
(Robert E. Taylor- Principal Investigator) | 1/1/97-12/30/2004
10% effort
SmithKline Beecham, Inc. |
|--|---|

Howard University – SmithKline Beecham Fellowship in Pharmaceutical Medicine & Clinical Pharmacology

This is a training grant to fund M.D. fellowships in clinical pharmacology & pharmaceutical medicine.

- | | |
|--|---|
| 3) National Institutes of Health
National Institute on Alcohol Abuse & Alcoholism
1 T32 AA014131
(Robert E. Taylor- Principal Investigator) | Scored/Not funded
April 1, 2003- March 31, 2008
10% effort
Grant amount: \$729,925 |
|--|---|

Minority Graduate Training in Alcohol Research

This is a training grant to support pre-doctoral students and post doctoral fellows in alcohol research. A resubmission is planned.

- | | |
|--|--|
| 4) National Institutes of Health
National Institute on Alcohol Abuse & Alcoholism | Scored/Pending Award
July 1, 2005-June 30, 2010 |
|--|--|

Clinical Pharmacology Training Grant

(Robert E. Taylor- Co-Investigator; Core Faculty)

This is a training grant submitted with Georgetown University School of Medicine and Children's National Medical Center for postdoctoral research training in Clinical pharmacology. Howard University faculty serves as Core Faculty, Training Faculty and Support Faculty. Fellows for all three schools will be supported by the grant. Dr. Michael A. Zasloff, Dean of Research and Translational Science at Georgetown University serves as the PI.

\$1,463,600

PHARMACEUTICAL CLINICAL TRIAL GRANTS -(Robert E. Taylor- Principal Investigator)

- 1) Glaxo Wellcome Inc.
Research Triangle Park, NC
A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Study to Investigate the Efficacy and Safety of Zanamivir (GG-167) – 10mg. Administered Twice a Day for Five Days in the Treatment of Symptomatic Influenza A and B Viral Infections in Adolescents and Adults (Protocol NAIA 3002), 12/15/97 to 6/30/98,
- 2) SmithKline Beecham Pharmaceuticals
Philadelphia, PA
A Study to evaluate the safety and tolerability of -----..... in patients with glucose-6-phosphate dehydrogenase deficiency and normal volunteers. -----
1/1/98 to 6/30/98.
- 3) Glaxo Wellcome Inc.
Research Triangle Park, N.C.....

CURRICULUM VITAE
R.E. Taylor, M.D., Ph.D

-----: A Randomized, Double-Blind, Multicenter Comparison of the Efficacy and Safety of Grepafloxacin (----- 400MG or 600MG Once Daily and -----500 MG Twice Daily in the Treatment of Patients with Acute Bacterial Exacerbations of Chronic Bronchitis. 1/1/98 to 6/30/98,

- 4) Glaxo Wellcome, Inc.
Research Triangle Park, NC.....
A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Parallel-Group Study to Investigate the Efficacy and Safety of ----- Administered Twice or Four Times a Day for the Treatment of Influenza A and B Viral Infections. ----- 10/1/95 to 3/1/96.
- 5) Glaxo Wellcome, Inc.
Research Triangle Park, N.C.
A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Parallel-Group Study to Investigate the Efficacy and Safety of ----- in the Prevention and/or Progression of Influenza A and B Viral Infections. ----- 10/1/95 to 3/1/96.
- 6) Convanee Laboratories/Proctor and Gamble
Madison, WS/Cincinnati, OH
A single rising and multiple dose safety and tolerability study of a Sodium Chlorite mouth rinse administered orally to Glucose-6-Phosphate Dehydrogenase deficient subjects and a multi-dose study in normal subjects. 5/1/2000-8/31/2000.

PUBLICATIONS:

ARTICLES

1. TAYLOR, R.E., E.S. Stitt, G.A. Robison and R.C. Hartmann: Characterization of prostaglandin-cyclic AMP interactions in human blood platelets. *Blood*, 42:944, 1973.
2. TAYLOR, R.E., T.S. Miya and J.H. Mennear: Effect of beta adrenergic agonists hepatic glycogenolysis in the rat; Effect of fasting on responsiveness. *Biochem. Pharmacol.*, 1973.
3. Blumberg, J.B., R.E. TAYLOR and F. Sulser: Norepinephrine sensitive Adenylate cyclase in the limbic forebrain and its blockade of pimozone. Possible role of limbic noradrenergic mechanisms in the mode of action of antipsychotics. *J. Pharm. Pharmacol.* 27:125, 1975.
4. TAYLOR, R.E. and M.E. Fant: Hypertension in the Black Community: An Overview. (Part I) *J. Tenn. Med. Assoc.* 68:983-985, 1975.
5. TAYLOR, R.E. and M.E. Fant: Hypertension in the Black Community: An Overview. (Part 2) *J. Tenn. Med. Assoc.* 69:32-33, 1976.
6. F.G. Dalldorf, R.E. TAYLOR and P.M. Blatt: Arteriosclerosis in severe hemophilia; A Postmortem Study. *Archives of Pathology and Laboratory Medicine*, 105:652-654, 1981.
7. TAYLOR, R.E. and P.M. Blatt: Clinical evaluation of the patient with bruising and bleeding. *J. Am. Acad. Dermatol.* 4:348-368, 1981.
8. Lesesne, H.R., P.M. Blatt, R.E. TAYLOR, G.C. White II and G. Johnson. Cirrhosis, variceal bleeding and distal splenorenal shunt in hemophilia. *Southern Medical Journal*, 75:1067-1068, 1982.

CURRICULUM VITAE
R.E. Taylor, M.D., Ph.D

9. Verma, P.S., R.L. Miller, R.E. TAYLOR, T.L. O'Donohue and R.G. Adams. Inhibition of canine lung angiotensin converting enzyme by ACTH and structurally related peptides. *Biochemical and Biophysical Res. Comm.* 104 (4): 1484, 1982.
10. White, G.C. II, R.E. TAYLOR, P.M. Blatt and H.R. Roberts. Treatment of a high titer anti-factor VIII antibody by continuous factor VIII administration. *Blood* 62: 141-145, 1983.
11. Perlin, E., R.E. TAYLOR, C. Peck. Clinical Pharmacokinetics: A simplified approach, Part I. *J. Natl. Med. Assoc.* 77:475-482, 1985.
12. Perlin, E., C. Peck and R.E. TAYLOR. Clinical Pharmacokinetics: A Simplified Approach, Part II. *J. Natl. Med. Assoc.*, 78: 835-842, 1986.
13. TAYLOR, R.E., R.V. Veiga. Beta Blockers, Hypertension, and Blacks -- Is the answer really in? *J. Natl. Med. Assoc.*, 78:851-856, 1986.
14. Adir, J., Janda S. M., Curry, C. L., TAYLOR, R.E., Poku, C.D. and Rotenberg, K. S. Comparative efficacy and safety of intermediate and controlled release hydralazine formulations in black hypertensive patients. *J. Clin. Hyper.* 9: 640-650, 1987.
15. Perlin, E., H. Finke, O. Castro, K. Bang, S. Rana, R.E. TAYLOR, K. Addo, J. Adir, A.K. Miller U.N. Elemeihe, C. Curry. Treatment of Sickle Cell Pain Crisis: A clinical trial of Diflunisal (Dolobid). *Clinical Trial J.*, 25: 254-264, 1988.
16. Verma, Pritam S. and R.E. TAYLOR. Effect of physostigmine on plasma angiotensin converting enzyme activity in the rat. *Res. Comm. in Chem. Path & Pharm.* 70: 245-248, 1990.
17. TAYLOR, R.E., and Panel, NIH Technology Assessment Workshop. The persian gulf experience and health. *J. Amer. Med. Assn.* 272: 391- 396, 1994.
18. Akinshola, B.E., Pritam S. Verma and R.E. TAYLOR. Effect of in vitro incorporation of prostanoid precursors, superoxide radical and hydrogen peroxide on platelet function. *Thrombosis Res.* 79:343-351, 1995
19. TAYLOR, R.E., and A. Gray, A . Venous Thromboembolism: Pathogenesis and Treatment. *J.Nat Med Assn.* In press 1998.
20. James, H., Tizabi, Y. and TAYLOR, R.E. A Rapid Method for the Simultaneous Measurement of Nicotine and Cotinine by Gas Chromatography/Mass Spectrometry. *J Chromatography B* 708:87-93, 1998.
21. Nduaka, C.I., TAYLOR, R.E., Green, S., Flynn, T., Sathyamoorthy, V., Sprando, R.L. and Johannessen, J.N. Glutamate Release From Chick Retina Explants in Response to Domoic Acid. *In Vitro & Molecular Toxicology.* 12:173-182, 1999.
22. Akinshola, B.E., TAYLOR, R.E., Ogunseitan, A.B., and Onaivi, E.S. Anadamide Inhibition of Recombinant AMPA Receptor subunits in *Xenopus* Oocytes is increased by Forskolin and 8-Bromo-cyclic AMP. *Naunyn Schmiedeberg's Arch.Pharmacology.* 360:242-248, 1999.
23. Poola, I., Williams, D.M., Koduri, S., Ramprakash, J., TAYLOR, R.E., and Hankins, W.D. Quantitation of Estrogen Receptor mRNA Transcript Copy Numbers in Breast Cancer Cell Lines and Tumors. *Analytical Biochemistry* 258:209-215, 1998.

CURRICULUM VITAE
R.E. Taylor, M.D., Ph.D

24. Dennis, G.C., Soni, D., Dehkordi, O., Millis, R.M., James, H., West, W.L., and TAYLOR, R.E. Analgesic Responses to Intrathecal Morphine in Relation to CSF Concentrations of Morphine-3, Beta-Gluconide and Morphine-6, Beta-Gluconide. *Life Sciences* 64:1725-1731, 1999
25. Tizabi, Y., Getachew, B. and TAYLOR, R.E. Alcohol-Preferring (P) Rats have Reduced Striatal Nicotinic Receptors Compared to Alcohol- Nonpreferring (NP) Rats. *Alcoholism: Clinical and Experimental Research*. Submitted 4/2004.
26. Guemei, A., Cottrell, J., Band, R., Hehman, H., Prudhomme, M., Pavlova, M., Ismail, A.S., Bowen, D., TAYLOR, R.E., Grem, J.L. and Takimoto, C.H. Human Plasma Carboxylesterase and butyrylcholinesterase Enzyme Activity: Correlations with SN-38 Pharmacokinetics During a Prolonged Infusion of Irinotecan. *Cancer Chemotherapy and Pharmacology*. 47: 283-90, 2001.
27. Y. Tizabi, B. Getachew, M. Davila-Garcia and R.E. TAYLOR. Alcohol Preference: Association with Reduced Striatal Nicotinic Receptors. *Alcohol & Alcoholism* 36:318-322, 2001
28. B.E. Akinshola, R. R. Stewart, L. Karvonen, R.E. TAYLOR and P. Liesi. Involvement of non-NMDA receptors in the rescue of Weaver cerebellar granule neurons and sensitivity to ethanol of cerebellar AMPA receptors in oocytes. *Molecular Brain Research* 93: 8-17, 2001
29. Y. Tizabi, R.L. Copeland, Jr., V. A. Louis and R.E. TAYLOR . Effects of Combined Systemic Alcohol and Central Nicotine Administration Into VTA on Dopamine Release in the Nucleus Accumbens. *Alcoholism: Clinical and Experimental Research*.26 394-399, 2002.
30. W. Yin, E. Akala and R. TAYLOR. Design of naltrexone-loaded hydrolyzable crosslinked nanoparticles. *International J. of Pharmaceutics*. 244: 9-19, 2002.
31. E. Bookman, R.E. TAYLOR, L. Adams-Campbell, and R.A. Kittles. DRD4 promoter SNPs and gender effects on Extraversion in American Americans. *Molecular Psychiatry*. 7:786-789, 2002.
32. Y. Tizabi, M. Al-Namaeh, K. Manaye, and R.E. TAYLOR. Protective Effects of Nicotine on Ethanol-Induced Toxicity in Cultured Cerebellar Granule Cells. *Neurotoxicity Research* 5:315-322, 2003.
33. J. P. Spence, T. Liang, C.J.P. Eriksson, R. E. TAYLOR, T. L. Wall, C. L. Ehlers and L. G. Carr. Evaluation of *Aldehyde Dehydrogenase 1* promoter polymorphisms identified in human populations. *Alcoholism: Clinical and Experimental Research*. 27: 1389-1394, 2003.
34. B. E. Akinshola, R. P. Yasuda, R. W. Peoples and R. E. TAYLOR. Ethanol Sensitivity of Recombinant Homomeric and Heteromeric AMPA Receptor Subunits Expressed in *Xenopus* Oocytes. *Alcoholism: Clinical and Experimental Research*. 27: 1876-1883, 2003.
35. submitted.....
.....
.....
36. R.E. Taylor Pharmacological and Cultural Consideration in Alcohol Treatment Clinical Trials: Issues in Clinical Research Related to Race and Ethnicity *Alcoholism: Clinical and Experimental Research*. 27:1345-1348, 2003.

CURRICULUM VITAE
R.E. Taylor, M.D., Ph.D

- 37. submitted
10/2003.....
.....
- 38. submitted
7/2004.....
.....
- 39. submitted.....
.....
- 40. accepted 7/2004.

□□□□□ □□□ □□□□□□□□□□

1. TAYLOR, R.E.: Pharmacological Evaluation of a series of 1, 2, 4-triazolyl-s-triazines, M.S. Thesis, Butler University, 1968.
2. TAYLOR, R.E.: Effect of beta adrenergic agonists on parameters of hepatic glycogenolysis in the rat: Effect of fasting on responsiveness. Ph.D. Thesis, Purdue University, 1972.
3. Oates, J.A., H.W. Seyberth, O. Oelz, A. Danon, R. Dean, B.J. Sweetman, R.E. TAYLOR and J.C. Frolich: Prostaglandins in the Etiology and Treatment of Cardiovascular Disease in: Proceedings of the Sixth International Congress of Pharmacology" (ed. J. Tuomisto and M.K. Paasonen, Vol. 5, "Clinical Pharmacology" (ed. M.J. Mattila) Pergamon Press, Oxford, 1976, pp. 139-149.
4. Blatt, R.M., R.E. TAYLOR, G.C. White, K.D. Zeitler, C.W. McMillan, H.S. Kingdon, D.C. Gabriel and H.R. Roberts: The treatment of disseminated intravascular coagulation: in "Chemistry and Biology of Heparin," (R.L. Lundblad, K.G. Mann, W.V. Brown and H.R. Roberts, eds. Elsevier/North-Holland, Inc., New York, 1981, pp. 497-502.
5. Blatt, P.M., G.C. White, C.W. McMillan, W.P. Webster, H.S. Kingdon, K.D. Zeitler, R.E. TAYLOR, K.M. Braunstein and H.R. Roberts: The treatment of hemorrhage in hemophiliacs with anti-factor VIII antibodies. In "Standardization of Coagulation Assays: An Overview." (D.A. Triplet, ed). College of American Pathologists, Stokie, Ill., 1982, pp. 305-317.
6. R.E. TAYLOR, Liverman, C.T., C.E. Ingalls, C.E. Fulco, H.M. Kipen and Committee on Toxicology and Environmental Health Information Resources for Health Professionals, Institute of Medicine, National Academy Press, Washington, D.C. 1997.
7. R.E. TAYLOR and Committee on Pharmacokinetics and Drug Interactions in the Elderly, Institute of Medicine, National Academy Press, Washington, D.C. 1997.
8. **"A Guide to Substance Abuse Services for Primary Care Physicians"**, Treatment Improvement Protocol (TIP) Series 24, Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment, PHS, 1997.
9. R.E. TAYLOR, **"Retail to Consumer Prescription Drug Pricing in Metropolitan Washington D.C. Region"**, February 20, 2001.

ABSTRACTS

CURRICULUM VITAE
R.E. Taylor, M.D., Ph.D

1. Blumberg, J.B., R.E. TAYLOR and F. Sulser: Modification by anti-psychotic drugs of the cyclic 3', 5' -AMP (CAMP) response to d-LSD in rat brain following microwave irradiation. *Fed. Proc.*, 32:303, 1973.
2. TAYLOR, R.E., E.S. Stitt, R.C. Hartman and N.V. Paniker: Prostaglandin (PG) - cyclic AMP interactions in human platelets: Role of lipid peroxidation (LPX). *The Pharmacol.* 16:309, 1974.
3. Oelz, O., H.W. Seyberth, R.E. TAYLOR, R. Oelz, A. Danon, T. Kennedy, J.C. Frolich and J.A. Oates: Effect of feeding of arachidonic acid and dihomo- γ -linolenic acid on platelet function, Proceedings of the IXth Annual Meeting of the European Society of Clinical Investigation, Rotterdam, The Netherlands, April 24-26, 1975. *European J. Clin. Invest.*, September, 1975.
4. Adams, R.G., R.L. Miller, R.E. TAYLOR, T.L. O'Donohue and P. Verma. In-Vitro inhibition of partially purified canine angiotensin I converting enzyme by ACTH peptides. *Clin. Res.* 29: 643A, 1981.
5. Lesesne, H.R., P. Blatt, R.E. TAYLOR, G. White, G. Johnson. Chronic liver disease, variceal bleeding and distal splenorenal shunt in hemophilia. *Gastroenterology* 80:139, 1981.
6. TAYLOR, R.E. "Microcirculatory pathology and the role of thrombosis in the hearing loss associated with sickle cell disease." Proceedings of the World Congress on Black Communication. Nairobi, Kenya. July 26-31, 1981.
7. TAYLOR, R.E. "Pharmacology of the Corticosteroids." Proceedings VIth Annual Clinical Symposium. Progress in Research and Clinical Application of Corticosteroids. Florida A & M University School of Pharmacy. Tallahassee, Florida, Feb. 20-22, 1981.
8. Verma, P., G. Sander, R.L. Miller, R.E. TAYLOR, T.L. O'Donohue and R.G. Adams. In vitro inhibition of partially purified canine angiotensin I converting enzyme by substance P. *Federation Proceedings* 41: 153I, 1982.
9. TAYLOR, R.E. Prostaglandin-Cyclic AMP interactions in human blood platelets: Role of lipid peroxidation. *Clin. Res.* 34:408A, 1986.
10. Verma, P.S., S. Noble, R.G. Adams, R.E. TAYLOR and R.L. Miller. Thyroxine increases serum angiotensin-converting enzyme in sheep. *Fed. Proc.*, 45:178, 1986.
11. Perlin, E., O. Castro, H. Finke, K.M. Bang, S. Rana, R.E. TAYLOR, and K. Addo. The value of diflunisal (Dolobid) in the treatment of painful sickle cell crisis. *Blood*, 68:64a, 1986.
12. Addo, K., A. Hosten, E. Perlin and R.E. TAYLOR. DDAVP shortens the bleeding time in uremia. *Blood*, 68:328a, 1986.
13. Verma, P., B.E. Akinshola and R.E. TAYLOR. Carbamate anticholinesterases stimulate cyclic adenosine monophosphate levels in human blood platelets. *J. Clin. Pharmacol.* 27:719, 1987.
14. Akinshola, B.E., P.S. Verma, and R.E. TAYLOR. Effect of prostaglandin precursors and superoxide radical on human blood platelet function in vitro. *The Pharmacologist*. A207, 1988.
15. Anand, S., R.E. TAYLOR, and Addo, F.E.K. Persistence of hematologic changes after clinical remission of thrombotic thrombocytopenic purpura. *Blood*. 74:95a, 1989.
16. Verma, Pritam S. and R.E. TAYLOR. Effect of physostigmine on plasma angiotensin converting enzyme (ACE) activity in rat. *The FASEB J.* 5:A851, 1991.

CURRICULUM VITAE
R.E. Taylor, M.D., Ph.D

17. Akinshola, B.E., R.E. TAYLOR, and M. Hollmann. Sensitivity of a Mutant AMPA Glutamate Receptor Subunit to Ethanol Inhibition. Research Society on Alcoholism. 1998.
18. Nduaka, C.I., R.E. TAYLOR, S. Green, T.J.Flynn, V. Sathyamoorthy, R.L. Sprando, and J.N. Johannessen. Endogenous Glutamate Released in Response to Domoic Acid Causes Excitotoxicity in Isolated Chick Retina. Society of Neuroscience. 1998.
19. Guemei A., Cottrell J., Band R., Prudhomme M., Bowen D., TAYLOR R., Hamilton J.M., Monahan B.M., Allegra C.J., Grem J.L., Takimoto C.H. Human plasma irinotecan carboxylesterase converting enzyme activity in patients receiving infusional irinotecan. American Association for Cancer Research 1999.
20. Akinshola, B.E., E.S. Onaivi, TAYLOR, R.E. Effects of N-Glycosylated side chains on ethanol sensitivity of recombinant AMPA glutamate receptor. Alcoholism: Clinical and Experimental Research 23: (No. 5) 8A, 1999.
21. Tizabi, Y., Getachew, B., Headings, V.E., TAYLOR, R.E. Nicotinic Cholinergic Receptors in various brain regions of alcohol preferring P and non-preferring NP rats. Alcoholism: Clinical and Experimental Research 23: (No. 5) 48A, 1999.
22. Y. Tizabi, R.I. Copeland, V.A. Louis, and R.E. TAYLOR Dizocilpine (MK0801) Administration into the Ventral Tegmental Area Blocks Alcohol Induced Dopamine Release in the Nucleus Accumbens. Research Society on Alcoholism June 2001
23. B.E. Akinshola and R.E. TAYLOR. Sites of Alcohol Actions on AMPA Glutamate Receptors. Research Society on Alcoholism June 2001.
24. TAYLOR, R.E., L. Flury, D.M. Scott, T. Foroud, N. Kalu, W. Bland, T.-K. Li, L. Carr. Allele Frequencies of ADH2 and ADH3 Polymorphisms Among Various Ethnic Groups. Alcoholism: Clinical and Experimental Research 27: (No. 5) 8A, 2003.
25. B.E. Akinshola, W. Johnson, E.S. Onaivi and R.E. TAYLOR. Ethanol Sensitivity of the Capsaicin/Vanilloid Receptor. ISBRA, Prague, September 2003.
26. D.M. Scott, C.D. Williams, N. Kalu, Y. Tizabi, L. Adams-Campbell and R.E. TAYLOR. Tobacco Use and Alcohol Dependence Among African Americans. Alcoholism: Clinical and Experimental Research 27: (No. 5) 150A, 2003.
27. B.E. Akinshola, J.T. Healey, R.E. TAYLOR and R.R. Stewart. Ethanol Sensitivity of a GLUR3 AMPA Receptor C-Terminal Truncation Mutant. Alcoholism: Clinical and Experimental Research 27: (No. 5) 91A, 2003.
28. M. Al-Namaeh, R. E. TAYLOR and Y. Tizabi. Ethanol-Induced Apoptosis in Primary Cultures of Rat Cortical and Cerebellar Cells is Blocked by Nicotine. Alcoholism: Clinical and Experimental Research 27: (No. 5) 93A, 2003.
29. Y. Tizabi, K.F. Manaye, E. Findeis and R.E. TAYLOR. Effects of Ethanol in an Animal Model of Depression. Alcoholism: Clinical and Experimental Research 27: (No. 5) 132A, 2003.
30. E. Akala, R. TAYLOR and P. Wiryacoonsakem. Colloidal Controlled Delivery System for Naltrexone. Alcoholism: Clinical and Experimental Research 27: (No. 5) 147A, 2003.

CURRICULUM VITAE
R.E. Taylor, M.D., Ph.D

31. R.J. Houston, L.O. Bauer, V.M. Hesselbrock, C.C. Duncan and R.E. Taylor. (October 2003). Antisocial Personality Disorder and alcohol dependence: N400 effects from a primed and unprimed word paradigm. *Psychophysiology* (abstract), 40, (supplement), S49.
32. K.Y. Walton, V.J. Marshall, N.N. Kalu, G. Cain and R.E. Taylor. The Cutaneous Manifestations of Alcohol Use Among African Americans. American College of Neuropsychopharmacology (ACNP), San Juan, December 2003.
33. B.R. Raysor, J. Kwagyan, N.Kalu, M. Powell-Davis, S. Duncan and R.E. TAYLOR. Alteration in Alcohol Pharmacokinetics by Oral Consumption of Malt Liquor Beverages. *Alcoholism: Clinical and Experimental Research* 28: (No. 5) 39A, 2004.
34. N.A. Ceballos, R.J. Houston, N.D. Smith, L.O. Bauer and R.E. TAYLOR. Independent and Combined Effects of Alcohol Dependence and Depression on the P300 ERP. *Alcoholism: Clinical and Experimental Research* 28: (No. 5) 21A, 2004.
35. Y. Tizabi, S.R. Hauser, K.F. Manaye, D.H. Overstreet and R.E. TAYLOR. Differential Effects of Alcohol in Different Animal Models of Depression. *Alcoholism: Clinical and Experimental Research* 28: (No. 5) 63A, 2004.
36. W.D. Johnson II, V. Parandaman, E.S. Onaivi, R.E. TAYLOR and E. Akinshola. Ethanol Sensitivity of a GluR1 AMPA Receptor Loop L3 Truncation Mutant and a Loop L3/C-Terminal Truncation Double Mutant. *Alcoholism: Clinical and Experimental Research* 28: (No. 5) 133A, 2004.
37. Y. Tizabi, R.L. Copeland, Jr, V.A. Louis, K.F. Manaye and R.E. TAYLOR. Preclinical Evidence for Alcohol-Nicotine Interactions. *Alcoholism: Clinical and Experimental Research* 28: (No. 5) 188A, 2004.
38. J. Kwagyan, N. Kalu and R.E. TAYLOR. A Correlated Logistic Regression Model for Population Pharmacodynamic Data. Abstract# 301105. The 2004 Joint Statistical Meeting, Toronto, August 8-12, 2004.
39. E. Akala, R. TAYLOR and P. Wiriyaconkasem. Naltrexone-Loaded Microspheres. *Alcoholism: Clinical and Experimental Research* 28: (No. 5) 114A, 2004

CURRICULUM VITAE
R.E. Taylor, M.D., Ph.D

v.05/04